

GENESIS

Annual Meeting of Shareholders

30 June 2009

Contents

1. International Biotechnology Industry
2. Genesis Achievements and Status
3. New Opportunities

Recent Headlines

Of the 343 biotech companies traded on US markets:

- 69 are trading below their cash level
- 135 public biotech companies are trading with less than one year of cash (42% of these have less than 6 months of cash)
- Over 110 companies have announced a corporate restructuring by slashing staff and putting promising projects in the refrigerator

BUT

- Biotech shows glimmer of an upward trend
[Burrill Report 1st June 2009]

Market Dynamics


- Big Pharma needs to acquire biotech products to fill pipelines
- Biotech creativity continuing
- Investor priority for clinical development
- Some government support for long term high risk research
- Still significant need for better treatments

Genesis History

- Established 1994:
 - First Biotech in New Zealand
 - Immunology and oncology focus
- AgBio programmes 1996 – 2006
 - Biofuel from shrubby hardwood
- International collaborations
 - Immunex, Corixa, Zenyaku Kogyo, SR Pharma, Evogenix etc
- Listed on NZX and ASX September 2000; Ticker GEN
- 3 bacterial derivative drugs taken to Phase II
 - 9 clinical trials run in USA, Europe, NZ, Brazil, Philippines
- Primary focus from 2004-2008 on RNAi therapeutics

Significant Commercial Achievements


1994 1996 1998 2000 2002 2004 2006 2008



Non-core Assets


- Significant assets held, not requiring any further investment, include:
 - Royalties on transgenic trees from ArborGen
 - Royalties on transgenic grasses from Wrightson
 - Equity position in USA Bioinformatic software company *Real Time Genomics Inc.*
 - Equity position in Pure Power Global

Intratumoural siRNA delivery




Two *i.t.* injections of siRNA loaded in vehicles

Nanoparticle-mediated intratumoral delivery of siRNA to tumour



Intravenous siRNA delivery to tumour



Single *i.v.* injection of siRNA loaded into vehicles and tumours collected 24 hrs later

siRNA Therapeutics

- Potent molecules developed

BUT

- Hard to achieve effective *in vivo* delivery
- Limited clinical development internationally
- Better technology needed

siRNA Delivery Problems

- “beyond a shadow of a doubt, is the number one problem”
- “I don’t think that we’re even close to finding a solution to this problem”*
- No magic bullets
- Liposomes and nanoparticles only moderately successful
- A new approach is required

*Alan Sachs (VP RNA therapeutics at Merck) discussing siRNA delivery RNAi news Vol. 6(38) September 25 2008

Genesis Gene Silencing Technology


| | siRNA | Antisense | Genesis Technology |
|---------------|-----------------|-----------|---------------------------|
| Design | Easy | Difficult | Easy |
| Activity | High | Low | High |
| IP protection | Difficult | Difficult | Simple |
| Delivery | Complex Vehicle | Naked | Simple |
| Cost | Expensive | Cheaper | Cheaper |

Single-stranded RNAi: a hybrid technology


A hybrid molecule would be:

- Easy to design based on siRNA algorithms
- Single-stranded for ease of delivery
- Effective at low concentrations
- Cheap to manufacture (no vehicle)
- Patentable reagent and drug

Principle of ssRNAi




Separate Strands are as Effective as siRNA Duplex



ssRNAi:
Potent
Gene
Silencing


Effective Control of Cancer Cell Growth



IP Protection

- IP review confirmed novelty and FTO
- Multiple patent applications filed with USPTO
- Potential applications in other modalities
- Ongoing strategy of reviewing patent landscape and filing additional patent applications

ssRNA Commercial Development



 Major value inflection: possible exit

Sharemarket Performance

GENESIS RES & DEV
as of 26-Jun-2009



Copyright 2009 Yahoo! Inc.

<http://finance.yahoo.com/>

Funding

- Genesis Cash balance at 30 June: \$0.3 million
 - Urgent need for more cash
 - Difficult to achieve major capital raising
- Plan to transfer project to new subsidiary
 - Subsidiary to be funded by international investment group
 - Government funding possible
- Share Purchase Plan

Share Purchase Plan

- Funds are required to maintain low cost shell while assets are realised and ssRNAi subsidiary established
- Assets to be realised include:
 - Stake in Real Time Genomics, Inc.
 - Stake in Pure Power Global
 - Debt owing by Pure Power Global
 - Royalties from Wrightson and ArborGen
- SPP terms to be determined

Further Opportunities

- Possible acquisition of another biotech business
 - Broaden Genesis pipeline
 - Further cash investment